Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06393452
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-04-26
Brief Title:
Safety Pharmacokinetics and Efficacy of PP405 in Adults With AGA
Sponsor:
Pelage Pharmaceuticals Inc
Organization:
Pelage Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Multicenter Double-blind Vehicle-controlled Phase 2a Study to Assess the Safety Pharmacokinetics and Efficacy of PP405 in Adults With Androgenetic Alopecia
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK following 28 days of administration
Detailed Description:
Safety Pharmacokinetics and Efficacy Study of PP405 in subjects with Androgenetic Alopecia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None